These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
11. Construction of a multivalent vaccine strain of Shigella flexneri and evaluation of serotype-specific immunity. Jennison AV; Roberts F; Verma NK FEMS Immunol Med Microbiol; 2006 Apr; 46(3):444-51. PubMed ID: 16553820 [TBL] [Abstract][Full Text] [Related]
12. Rationalizing the design of a broad coverage Shigella vaccine based on evaluation of immunological cross-reactivity among S. flexneri serotypes. Citiulo F; Necchi F; Mancini F; Rossi O; Aruta MG; Gasperini G; Alfini R; Rondini S; Micoli F; Rappuoli R; Saul A; Martin LB PLoS Negl Trop Dis; 2021 Oct; 15(10):e0009826. PubMed ID: 34644291 [TBL] [Abstract][Full Text] [Related]
13. Monoclonal Antibodies to Shigella Lipopolysaccharide Are Useful for Vaccine Production. Lin J; Smith MA; Benjamin WH; Kaminski RW; Wenzel H; Nahm MH Clin Vaccine Immunol; 2016 Aug; 23(8):681-8. PubMed ID: 27280622 [TBL] [Abstract][Full Text] [Related]
14. Cross-reactivity of Shigella flexneri serotype 2a O antigen antibodies following immunization or infection. Van De Verg LL; Bendiuk NO; Kotloff K; Marsh MM; Ruckert JL; Puryear JL; Taylor DN; Hartman AB Vaccine; 1996 Aug; 14(11):1062-8. PubMed ID: 8879103 [TBL] [Abstract][Full Text] [Related]
15. Quantitative analysis of IgG class and subclass and IgA serum response to Shigella sonnei and Shigella flexneri 2a polysaccharides following vaccination with Shigella conjugate vaccines. Robin G; Keisari Y; Slepon R; Ashkenazi S; Cohen D Vaccine; 1999 Aug; 17(23-24):3109-15. PubMed ID: 10462247 [TBL] [Abstract][Full Text] [Related]
16. Development, Interlaboratory Evaluations, and Application of a Simple, High-Throughput Nahm MH; Yu J; Weerts HP; Wenzel H; Tamilselvi CS; Chandrasekaran L; Pasetti MF; Mani S; Kaminski RW mSphere; 2018 Jun; 3(3):. PubMed ID: 29898979 [No Abstract] [Full Text] [Related]
17. A synthetic carbohydrate-protein conjugate vaccine candidate against Shigella flexneri 2a infection. Phalipon A; Tanguy M; Grandjean C; Guerreiro C; Bélot F; Cohen D; Sansonetti PJ; Mulard LA J Immunol; 2009 Feb; 182(4):2241-7. PubMed ID: 19201878 [TBL] [Abstract][Full Text] [Related]
18. Shigella-specific antibodies in the first year of life among Zambian infants: A longitudinal cohort study. Chisenga CC; Bosomprah S; Simuyandi M; Mwila-Kazimbaya K; Chilyabanyama ON; Laban NM; Bialik A; Asato V; Meron-Sudai S; Frankel G; Cohen D; Chilengi R PLoS One; 2021; 16(5):e0252222. PubMed ID: 34043697 [TBL] [Abstract][Full Text] [Related]
19. Vaccination with Shigella flexneri 2a conjugate induces type 2a and cross-reactive type 6 antibodies in humans but not in mice. Farzam N; Ramon-Saraf R; Banet-Levi Y; Lerner-Geva L; Ashkenazi S; Kubler-Kielb J; Vinogradov E; Robbins JB; Schneerson R Vaccine; 2017 Sep; 35(37):4990-4996. PubMed ID: 28797729 [TBL] [Abstract][Full Text] [Related]